Evidence map›Paper›PMID 38994161›Full record

ArticleWorld journal of gastrointestinal oncology2024

Association between

Carlos A Castaneda, Miluska Castillo, Luis A Bernabe, Joselyn Sanchez, Matteo Fassan, Katherine Tello, Ignacio Ivan Wistuba, Ivan Chavez Passiuri, Eloy Ruiz, Juvenal Sanchez and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Carlos A CastanedaFaculty of Health Sciences, Universidad Cientifica del Sur, Lima 15038, Peru.
Miluska CastilloDepartment of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Luis A BernabeDepartment of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Joselyn SanchezDepartment of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Matteo FassanDepartment of Medicine, Surgical Pathology & Cytopathology Unit, University of Padua, Padua 35121, Italy.
Katherine TelloDepartment of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Ignacio Ivan WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Ivan Chavez PassiuriDepartment of Abdominal Surgery, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Eloy RuizDepartment of Abdominal Surgery, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Juvenal SanchezDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Fernando BarredaDepartment of Medical Specialties, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Daniel ValdiviaDepartment of Medical Specialties, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Yaqueline BazanDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Milagros Abad-LichamDepartment of Pathology, Instituto Regional de Enfermedades Neoplasicas del Norte, Trujillo 13001, Peru.
Claudio MengoaDepartment of Surgery, Instituto Regional de Enfermedades Neoplasicas del Sur, Arequipa 04002, Peru.
Hugo FuentesDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Paola MontenegroDepartment of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Ebert PoquiomaDepartment of Epidemiology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Raul AlatristaDepartment of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
Claudio J FloresUnidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima 15038, Peru.
Luis TaxaDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe influence of

aimTo determine the rates of deficient mismatch-repair (dMMR), HER2-status and

methodsSamples from 503 resected GC tumors were included and TIL levels were evaluated following the international-TILs-working-group recommendations with assessment of the intratumoral (IT), stromal (ST) and invasive-border (IB) compartments. The density of CD3, CD8 and CD163 immune cells, and dMMR and HER2-status were determined by immunohistochemistry (IHC).

resultsdMMR was found in 34.4%, HER2+ in 5% and

conclusionTIL levels were related to dMMR and

Indexed as

Gastric cancerHelicobacter pyloriHER2LymphocytesMacrophagesMismatch repair

Identifiers

PMID38994161
PMCPMC11236231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.